The life sciences industry just delivered some eye-popping numbers. While lung cancer therapeutics alone is projected to jump from $30.2 billion in 2024 to $49.5 billion by 2030, the real story is happening in the DNA space, where the read, write, and edit market is racing toward $67.7 billion by 2030 at a 21.2% CAGR.
What's driving this surge? It's not just one breakthrough — it's a convergence. Rising infectious disease cases are boosting DNA diagnostics demand, while the push for early cancer detection is creating new market opportunities. Add in positive private funding for genome editing and increased government R&D spending, and you've got a perfect growth storm.
The innovation pipeline looks particularly strong. CRISPR-based diagnostics are moving beyond the lab, liquid biopsy technologies using biomarkers like ctDNA are gaining traction, and AI-enabled diagnostics are transforming how we approach disease detection. Companies like Novartis, Illumina, and Thermo Fisher Scientific are doubling down — Thermo Fisher alone is investing $2 billion over four years in U.S. expansion.
But here's the reality check: high sequencing costs, regulatory uncertainty around genome editing, and a critical shortage of specialized talent are creating headwinds. The promise is massive, but execution remains challenging.
Want the full picture? Download the free overview of our report State of the Life Sciences Industry - 2026 First Quarter Review for insights on emerging technologies, investment patterns, and market dynamics shaping the next phase of life sciences growth.
Download the Free Report Overview →
